Tampostat for Management of Postpartum Hemorrhage

Phase 1

Terminated

• Conditions: Postpartum Hemorrhage
• Interventions: Device: Condom catheter tamponade; Device: Tampostat

• Registration Number: NCT02416089
• Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Brief Summary

The purpose of the study is to evaluate the safety, feasibility and applicability of a new device 'Tampostat' in the management of primary postpartum hemorrhage and compare the efficacy of 'Tampostat' in terms of arresting primary PPH with that of the conventional condom catheter.

Detailed Description

This will be a 2-year study having two parts. Part A will be a Proof of Concept (POC) study that will be conducted at the Obstetrical Ward of Shaheed Suhrawardi Medical College Hospital (ShSMCH) and Dhaka Medical College Hospital (DMCH). There is no sample size estimation of this POC study that will assess safety, feasibility and applicability of using Tampostat on 5 consenting women with PPH for each hospital. Part B of the study will be an open label, randomized clinical trial that will be conducted at the Obstetrical Ward of Dhaka Medical College Hospital (DMCH). In this part, 344 consenting women with primary PPH will be enrolled, and allocated to either Tampostat or the control intervention in equal numbers per randomization (172 patients in each arm). In both these parts, Tampostat will be used only when Active Management of Third Stage of Labour (AMTSL) has failed to prevent PPH within 24 hours after delivery. All the doctors involved in the provision of care and treatment to PPH patients will be trained on the WHO's standard of care; they will also receive training on appropriate use of the devices to be used in this trial. An expert committee constituted of OBGYN professionals, clinical trial specialists, and statisticians will oversee the technical management of patients, data collection and their procedures, and ethical issues in this trial.

Study Timeline

• Study First Submitted: 2015-03-16
• Study Start: 2015-04
• Study First Submitted QC: 2015-04-09
• Study First Posted: 2015-04-14
• Status Verified: 2016-11
• Primary Completion: 2016-12
• Study Completion: 2016-12
• Last Update Submitted: 2018-11-22
• Last Update Posted: 2018-11-26

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 344

Inclusion Criteria

1. Women who delivered their baby at the site hospital, or attended the site hospital with PPH that started within the last 24 hours.
2. Women with primary PPH have received AMTSL.
3. PPH is due to atonic uterus.
4. Provides written informed consent for enrolment in the study.

Exclusion Criteria

1. Primary PPH caused by retained placenta or ruptured uterus.
2. Women who delivered before 28 weeks of gestation.
3. Women not willing to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Condom catheter tamponade	Condom catheter tamponade	Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.
Tampostat	Tampostat	Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)

Primary Outcome Measures

Name	Time	Method
Safety of Tampostat as measured by number of serious adverse events in primary PPH management	2 months	The safety of Tampostat \[no. of Serious adverse events i.e. Incidence of air embolism, injury to the uterine wall, pain during inflation of condom \& continuation of vaginal /uterine bleeding during use of Tampostat\] in primary PPH management.
Efficacy of Tampostat as measured by number of successful cases in arresting bleeding in Primary PPH	12 months	Efficacy \[number of successful cases in arresting bleeding due to primary PPH from atonic uterus\] of Tampostat in the management of primary postpartum hemorrhage (PPH)
Comparison of the efficacy of Tampostat as measured by number of successful cases in arresting primary PPH and the time takes to arrest the bleeding with that of the condom catheter tamponade	12 months	Comparison of the efficacy of Tampostat in terms of arresting primary PPH due to atonic uterus with that of the conventional condom catheter tamponade \[no. of successful cases in arresting primary post partum bleeding using Tampostat and condom catheter and the time both takes to arrest the bleeding\]

Secondary Outcome Measures

Name	Time	Method
Applicability of Tampostat as measured by rating by service providers using pre established scoring system in the management of primary PPH	2 months	Applicability\[rating by service providers on applicability of the device using pre established scoring system\]of Tampostat in the management of primary PPH due to atonic uterus.
Feasibility as measured by number of physicians consider Tampostat as a feasible device in arresting primary PPH	2 months	The feasibility of Tampostat\[number of physicians consider Tampostat as a feasible device in arresting primary PPH due to atonic uterus\] in the management of primary PPH by

Trial Locations

Locations (1)

Obstetrical Ward of Shaheed Suhrawardi Medical College Hospital (ShSMCH) and Dhaka Medical College Hospital (DMCH); 🇧🇩 Dhaka, Bangladesh